General Information of Drug (ID: DMPFGL8)

Drug Name
BAL-101553 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Recurrent glioblastoma 2A00.00 Phase 1 [2]
Cross-matching ID
PubChem CID
45259014
CAS Number
CAS 1263384-43-5
TTD Drug ID
DMPFGL8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Tubulin (TUB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [4]
Vinorelbine DMVXFYE Advanced cancer 2A00-2F9Z Approved [5]
Cabazitaxel DMPAZHC Breast cancer 2C60-2C65 Approved [6]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [7]
Ixabepilone DM2OZ3G Breast cancer 2C60-2C65 Approved [6]
Eribulin DM1DX4Q Breast cancer 2C60-2C65 Approved [6]
Epothilon DMITJRU Ovarian cancer 2C73 Phase 3 [8]
DOLASTATIN-10 DMDUV1S Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
BMS-188797 DML1CK2 Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
Indibulin DM6OFJ8 Advanced sarcoma 2A60-2C35 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Tubulin beta (TUBB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vincristine DMINOX3 Acute lymphoblastic leukaemia 2A85 Approved [12]
Albendazole DMYZ57N Echinococcus granulosus infectious disease Approved [13]
Vindesine DMVR628 Acute lymphoblastic leukaemia 2A85 Approved [14]
Taxol DMUOT9V Breast cancer 2C60-2C65 Approved [15]
Mebendazole DMO14SG Ascariasis 1F62 Approved [13]
Plinabulin DMD7L48 Non-small-cell lung cancer 2C25.Y Phase 3 [16]
Batabulin DMHWE5R Solid tumour/cancer 2A00-2F9Z Phase 2/3 [17]
ABT-751 DMNG35S Solid tumour/cancer 2A00-2F9Z Phase 2 [18]
DOLASTATIN-10 DMDUV1S Solid tumour/cancer 2A00-2F9Z Phase 2 [19]
BNC-105 DMJC8DR Mesothelioma 2C51.2 Phase 2 [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inhibitor [2]
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Inhibitor [3]

References

1 ClinicalTrials.gov (NCT02490800) Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015 Jun;62(6):1106-9.
4 Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
5 Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9.
6 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
7 Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
8 Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
9 Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15. J Med Chem. 1998 Apr 23;41(9):1524-30.
10 Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003 Nov 1;9(14):5187-94.
11 2011 Pipeline of ZioPharm.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13 Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
14 Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36.
15 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
16 NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.
17 Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605.
18 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
19 Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
20 The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60.